{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:35:26Z","timestamp":1759538126604,"version":"build-2065373602"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The current standard first-line therapy for aplastic anemia (AA) consists of antithymocyte globulin (ATG), cyclosporine, and thrombopoietin receptor agonists (TPO-RAs). A subset of patients exhibit treatment intolerance or develop refractory\/relapsed disease, for whom treatment options are limited. Umbilical cord blood exhibits immunomodulatory effects, regulates the bone marrow microenvironment, and promotes hematopoietic reconstitution, thereby demonstrating therapeutic potential for AA. In this prospective clinical study, cord blood infusion was administered in combination with cyclosporine and hetrombopag for the treatment of AA (n\u2009=\u200911). The primary endpoint was the hematologic response at 3\u00a0months post-treatment. By 3\u00a0months, 8 of 11 patients achieved at least one lineage hematologic response. By 6\u00a0months, 3 patients attained complete response (CR), 5 achieved partial response (PR), yielding an overall response rate (ORR) of 8\/11. After a median follow-up of 23\u00a0months, 5 patients maintained sustained CR and 3 sustained PR, with the ORR remaining at 8\/11. The median time to trilineage response was 112\u00a0days (range: 18\u2013168\u00a0days) among 8 responsive patients. Two patients with SAA refractory to treatment succumbed to pulmonary infections and pneumorrhagia. No significant adverse reactions were observed in cord blood-treated patients. This small-scale study introduces a novel regimen combining umbilical cord blood infusion, cyclosporine, and hetrombopag for treating aplastic anemia. With a median follow-up of 23\u00a0months, the overall response rate reached 8\/11 and the CR rate 5\/11. The safety and efficacy of this regimen were preliminarily assessed, suggesting a potential therapeutic alternative for patients ineligible for standard immunosuppressive therapy.<\/jats:p>","DOI":"10.1038\/s41598-025-18188-3","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:49:30Z","timestamp":1759488570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Umbilical cord blood infusion in the treatment of aplastic anemia: A single center prospective study"],"prefix":"10.1038","volume":"15","author":[{"given":"Xianghui","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhirui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianjie","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"17","key":"18188_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young, N. S. Aplastic anemia. N. Engl. J. Med. 379(17), 1643\u20131656 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"18188_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2016","unstructured":"Killick, S. B. et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br. J. Haematol. 172(2), 187\u2013207 (2016).","journal-title":"Br. J. Haematol."},{"key":"18188_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/asheducation-2011.1.76","volume":"2011","author":"EC Guinan","year":"2011","unstructured":"Guinan, E. C. Diagnosis and management of aplastic anemia. Hematol. Am. Soc. Hematol. Educ. Program 2011, 76\u201381 (2011).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"1","key":"18188_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1200931","volume":"367","author":"MJ Olnes","year":"2012","unstructured":"Olnes, M. J. et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N. Engl. J. Med. 367(1), 11\u201319 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"18188_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/blood-2011-05-352328","volume":"119","author":"P Scheinberg","year":"2012","unstructured":"Scheinberg, P. et al. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 119(2), 345\u2013354 (2012).","journal-title":"Blood"},{"issue":"18","key":"18188_CR6","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1182\/blood-2014-05-573642","volume":"124","author":"P Scheinberg","year":"2014","unstructured":"Scheinberg, P. et al. Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Blood 124(18), 2820\u20132823 (2014).","journal-title":"Blood"},{"issue":"11","key":"18188_CR7","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1182\/blood-2009-06-225375","volume":"115","author":"RA Brodsky","year":"2010","unstructured":"Brodsky, R. A. et al. High-dose cyclophosphamide for severe aplastic anemia: Long-term follow-up. Blood 115(11), 2136\u20132141 (2010).","journal-title":"Blood"},{"issue":"13","key":"18188_CR8","doi-asserted-by":"publisher","first-page":"4668","DOI":"10.1182\/blood-2002-02-0494","volume":"100","author":"JF Tisdale","year":"2002","unstructured":"Tisdale, J. F. et al. Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): Follow-up of a randomized trial. Blood 100(13), 4668\u20134670 (2002).","journal-title":"Blood"},{"issue":"5","key":"18188_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1056\/NEJMoa1103975","volume":"365","author":"P Scheinberg","year":"2011","unstructured":"Scheinberg, P. et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N. Engl. J. Med. 365(5), 430\u2013438 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"18188_CR10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3324\/haematol.13829","volume":"94","author":"P Scheinberg","year":"2009","unstructured":"Scheinberg, P. et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: A prospective randomized study. Haematologica 94(3), 348\u2013354 (2009).","journal-title":"Haematologica"},{"issue":"6","key":"18188_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1365-2141.2006.06085.x","volume":"133","author":"P Scheinberg","year":"2006","unstructured":"Scheinberg, P. et al. Treatment of severe aplastic anaemia with combined immunosuppression: Anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br. J. Haematol. 133(6), 606\u2013611 (2006).","journal-title":"Br. J. Haematol."},{"issue":"6","key":"18188_CR12","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjh.17403","volume":"194","author":"P Scheinberg","year":"2021","unstructured":"Scheinberg, P. Acquired severe aplastic anaemia: How medical therapy evolved in the 20th and 21st centuries. Br. J. Haematol. 194(6), 954\u2013969 (2021).","journal-title":"Br. J. Haematol."},{"issue":"13","key":"18188_CR13","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed, Y. Y. Hetrombopag: First Approval. Drugs 81(13), 1581\u20131585 (2021).","journal-title":"Drugs"},{"key":"18188_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2020-137319","volume":"136","author":"F Zhang","year":"2020","unstructured":"Zhang, F. et al. A multicenter, open-label, single-arm, phase 2 study to evaluate the efficacy and safety of hetrombopag in patients with severe aplastic anemia (SAA). Blood 136, 3\u20134 (2020).","journal-title":"Blood"},{"key":"18188_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fimmu.2017.00329","volume":"8","author":"A Sarvaria","year":"2017","unstructured":"Sarvaria, A. et al. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front. Immunol. 8, 329 (2017).","journal-title":"Front. Immunol."},{"key":"18188_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.922120","volume":"12","author":"T Cheng","year":"2022","unstructured":"Cheng, T. et al. Comparison of outcomes of haploidentical peripheral blood stem cell transplantation supported by third-party cord blood versus human leukocyte antigen-matched sibling peripheral blood stem cell transplantation in hematologic malignancy patients. Front. Oncol. 12, 922120 (2022).","journal-title":"Front. Oncol."},{"issue":"1","key":"18188_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-024-01820-5","volume":"9","author":"B Zhou","year":"2024","unstructured":"Zhou, B. et al. Haploidentical hematopoietic cell transplantation with or without an unrelated cord blood unit for adult acute myeloid leukemia: A multicenter, randomized, open-label, phase 3 trial. Signal Transduct. Target Ther. 9(1), 108 (2024).","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"18188_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41392-024-02065-y","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia. Signal Transduct. Target Ther. 9(1), 358 (2024).","journal-title":"Signal Transduct. Target Ther."},{"issue":"7","key":"18188_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nrc2418","volume":"8","author":"MJ Sullivan","year":"2008","unstructured":"Sullivan, M. J. Banking on cord blood stem cells. Nat. Rev. Cancer 8(7), 555\u2013563 (2008).","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"18188_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jcyt.2019.08.004","volume":"21","author":"J Aziz","year":"2019","unstructured":"Aziz, J. et al. Systematic review of controlled clinical studies using umbilical cord blood for regenerative therapy: Identifying barriers to assessing efficacy. Cytotherapy 21(11), 1112\u20131121 (2019).","journal-title":"Cytotherapy"},{"issue":"10","key":"18188_CR21","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.bbmt.2017.05.032","volume":"23","author":"M Rizk","year":"2017","unstructured":"Rizk, M. et al. Cell-Based therapy using umbilical cord blood for novel indications in regenerative therapy and immune modulation: An updated systematic scoping review of the literature. Biol. Blood Marrow Transplant. 23(10), 1607\u20131613 (2017).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"18188_CR22","unstructured":"Red Cell Diseases Group, Society of Hematology, Chinese Medical Association, Fu R, Li LJ, et al. Chinese guidelines for the diagnosis and treatment of aplastic anemia (2022 edition). Chin J Hematol. 2022;43(11):8. (in Chinese)"},{"issue":"16","key":"18188_CR23","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley, D. M. et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N. Engl. J. Med. 376(16), 1540\u20131550 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"18188_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","volume":"386","author":"R Peffault de Latour","year":"2022","unstructured":"Peffault de Latour, R. et al. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N. Engl. J. Med. 386(1), 11\u201323 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"18188_CR25","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1007\/s00277-024-05941-3","volume":"103","author":"S Shen","year":"2024","unstructured":"Shen, S. et al. Adding hetrombopag to cyclosporine a improved response of patients with newly diagnosed transfusion-dependent non-severe aplastic anemia. Ann. Hematol. 103(10), 4247\u20134249 (2024).","journal-title":"Ann. Hematol."},{"issue":"1","key":"18188_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-023-00377-3","volume":"12","author":"W Yang","year":"2023","unstructured":"Yang, W. et al. Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: Early outcomes of a prospective pilot study. Exp. Hematol. Oncol. 12(1), 16 (2023).","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"18188_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/ejh.14418","volume":"115","author":"B Zhang","year":"2025","unstructured":"Zhang, B. et al. Comparison of hetrombopag and eltrombopag added to first-line immunosuppressive therapy in severe aplastic anemia. Eur. J. Haematol. 115(1), 64\u201371 (2025).","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"18188_CR28","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00277-025-06335-9","volume":"104","author":"J Li","year":"2025","unstructured":"Li, J. et al. The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia. Ann. Hematol. 104(3), 1515\u20131525 (2025).","journal-title":"Ann. Hematol."},{"issue":"12","key":"18188_CR29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.24897","volume":"92","author":"P Boddu","year":"2017","unstructured":"Boddu, P. et al. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am. J. Hematol. 92(12), 1295\u20131302 (2017).","journal-title":"Am. J. Hematol."},{"issue":"4","key":"18188_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ajh.27611","volume":"100","author":"B Fattizzo","year":"2025","unstructured":"Fattizzo, B. et al. Elderly patients with aplastic anemia: Treatment patterns and outcomes in the real world. Am. J. Hematol. 100(4), 584\u2013591 (2025).","journal-title":"Am. J. Hematol."},{"issue":"6","key":"18188_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","volume":"1","author":"H Yoshihara","year":"2007","unstructured":"Yoshihara, H. et al. Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 1(6), 685\u2013697 (2007).","journal-title":"Cell Stem Cell"},{"key":"18188_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2003.tb03228.x","volume":"996","author":"M Ballmaier","year":"2003","unstructured":"Ballmaier, M. et al. Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: Development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann. N. Y. Acad. Sci. 996, 17\u201325 (2003).","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"18188_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3324\/haematol.2010.030536","volume":"96","author":"X Feng","year":"2011","unstructured":"Feng, X. et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 96(4), 602\u2013606 (2011).","journal-title":"Haematologica"},{"issue":"21","key":"18188_CR34","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1182\/bloodadvances.2018020248","volume":"2","author":"P Scheinberg","year":"2018","unstructured":"Scheinberg, P. Activity of eltrombopag in severe aplastic anemia. Blood Adv. 2(21), 3054\u20133062 (2018).","journal-title":"Blood Adv."},{"issue":"12","key":"18188_CR35","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s00277-022-04968-8","volume":"101","author":"W Yang","year":"2022","unstructured":"Yang, W. et al. Iron chelation of hetrombopag in aplastic anemia: A post hoc analysis of a phase II study. Ann. Hematol. 101(12), 2611\u20132616 (2022).","journal-title":"Ann. Hematol."},{"key":"18188_CR36","unstructured":"Qi Qu. Role and Mechanistic Investigation of Umbilical Cord Blood-Derived Endothelial Progenitor Cells in Hematopoietic Stem Cell Transplantation [D]; Soochow University, 2016. (in Chinese)"},{"issue":"1","key":"18188_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjh.17190","volume":"192","author":"JH Jang","year":"2021","unstructured":"Jang, J. H. et al. Efficacy and safety of romiplostim in refractory aplastic anaemia: A Phase II\/III, multicentre, open-label study. Br. J. Haematol. 192(1), 190\u2013199 (2021).","journal-title":"Br. J. Haematol."},{"issue":"11","key":"18188_CR38","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1016\/S2352-3026(19)30153-X","volume":"6","author":"JW Lee","year":"2019","unstructured":"Lee, J. W. et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: A dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 6(11), e562\u2013e572 (2019).","journal-title":"Lancet Haematol."},{"issue":"6","key":"18188_CR39","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1182\/bloodadvances.2023010959","volume":"8","author":"K Mitani","year":"2024","unstructured":"Mitani, K. et al. Long-term efficacy and safety of romiplostim in refractory aplastic anemia: Follow-up of a phase 2\/3 study. Blood Adv. 8(6), 1415\u20131419 (2024).","journal-title":"Blood Adv."},{"issue":"3","key":"18188_CR40","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41375-020-0950-6","volume":"35","author":"K Hosokawa","year":"2021","unstructured":"Hosokawa, K. et al. High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. Leukemia 35(3), 906\u2013909 (2021).","journal-title":"Leukemia"},{"key":"18188_CR41","doi-asserted-by":"publisher","first-page":"204062072311913","DOI":"10.1177\/20406207231191310","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Comparison of eltrombopag and avatrombopag in the treatment of refractory\/relapsed aplastic anemia: A single-center retrospective study in China. Ther. Adv. Hematol. 14, 20406207231191310 (2023).","journal-title":"Ther. Adv. Hematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18188-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18188-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18188-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:49:33Z","timestamp":1759488573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18188-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18188"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18188-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in compliance with the principles of the Declaration of Helsinki and was approved by the Ethics Review Committee of Shandong Provincial Third Hospital. All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained for all patients before they were enrolled in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent for publication was obtained from the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"34607"}}